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Intravitreal triamcinolone inhibits choroidal neovascularization. To investigate if vascular endothelial growth factor (VEGF) is
aﬀected, we examined VEGF expression after intravitreal triamcinolone administration in rat retina. Using in situ hybridization, we
have found dense clustered VEGF mRNA signals in the retinal pigment epithelium, moderate patchy signals in the inner nuclear
layer, and positive labeling in a sub-population of ganglion cells. Densitometry and northern blot analysis revealed no signiﬁcant
alteration of VEGF mRNA expression pattern and level 3–21 days after triamcinolone injection. Our data indicate that intravitreal
triamcinolone does not aﬀect basal VEGF mRNA expression in normal adult rat retina.
 2003 Elsevier Ltd. All rights reserved.
Keywords: Triamcinolone; Vascular endothelial growth factor; Neovascularization; Age-related macular degeneration1. Introduction
Sub-retinal choroidal neovascularization (CNV) in
the macula is responsible for the majority of severe vi-
sion loss due to age-related macular degeneration
(AMD). Traditional argon or krypton laser photoco-
agulation was proven beneﬁcial in the Macular Photo-
coagulation Study (Macular Photocoagulation Study
Group, 1991), but is limited to classic CNV and cur-
rently used for treatment of parafoveal classic CNV.
Photodynamic therapy (PDT), recently approved for
exudative AMD, is now a popular treatment for sub-
foveal or juxtafoveal CNV and has proven beneﬁcial for
approximately 60%–70% CNV patients (Treatment of
Age-Related Macular Degeneration with Photodynamic
Therapy (TAP) Study Group, 1999, 2001). However, its* Corresponding author. Address: Department of Ophthalmology,
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doi:10.1016/j.visres.2003.09.027limitations are that majority of patients needs multiple
treatments, that it is not eﬀective for some patients and
only approved for lesions with more than 50% classic
CNV. Triamcinolone has long been used as an intravi-
treal anti-angiogenesis agent in animal models. Tano
et al. ﬁrst observed that intravitreal triamcinolone ace-
tonide signiﬁcantly reduced retinal neovascularization
and ﬁbrosis caused by autotransplanted ﬁbroblasts in
rabbit (Tano, Chandler, & Machemer, 1980). This was
later conﬁrmed by other studies (Antoszyk, Gottlieb,
Machemer, & Hatchell, 1993). Intravitreal triamcino-
lone inhibited retinal neovascularization in animal
models of branch retinal vein occlusion (Danis, Bing-
aman, Yang, & Ladd, 1996). Penfold, Gyory, Hunyor,
and Billson (1995) ﬁrst employed intravitreal triamcin-
olone on human exudative AMD patients and found
that it signiﬁcantly reduced severe vision loss, and sta-
bilized CNV membrane on ﬂuorescein angiogram. This
clinical study was subsequently conﬁrmed and supple-
mented by other studies (Challa et al., 1998; Danis,
Ciulla, Pratt, & Anliker, 2000). A recent study showed
that intravitreal triamcinolone stabilized recurrent CNV
in patients with prior laser treatments (Ranson, Danis,
Ciulla, & Pratt, 2002). Intravitreal triamcinolone also
inhibits development of sub-retinal neovascularization
350 H. Gao et al. / Vision Research 44 (2004) 349–356induced by laser treatment in rat models (Ciulla, Cri-
swell, Danis, & Hill, 2001). Although these studies
showed that triamcinolone inhibited retinal and CNV,
its mechanisms of anti-angiogenesis remain unknown.
It has been well known that vascular endothelial
growth factor (VEGF) is an important angiogenesis
factor in proliferative diabetic retinopathy (Adamis
et al., 1994; Aiello et al., 1994; Malecaze et al., 1994), in
animal models of retinal hypoxia (Pierce, Avery, Foley,
Aiello, & Smith, 1995), and in retinal vein occlusion
(Miller et al., 1994). Transgenic mice with VEGF over-
expression showed signiﬁcant pre-retinal and intra-
retinal neovascularization (Okamoto et al., 1997).
Neutralizing VEGF antibody (Aiello et al., 1995) or
VEGF antisense oligodeoxynucleotides (Robinson et al.,
1996) reduced retinal neovascularization signiﬁcantly in
animal models. Thus VEGF plays a central role in the
development of retinal neovascularization due to retinal
ischemia.
Despite extensive studies, the role of VEGF in the
development of sub-retinal CNV is not as certain as that
in the retinal neovascularization. Evidence has been
accumulated that VEGF expression is increased in CNV
membranes in human exudative AMD patients (Frank,
1997, 1999) and in animal models induced by laser
treatment (Yi et al., 1997). Sub-retinal implantation of
VEGF-impregnated microspheres in monkey lead to the
development of CNV similar to those seen in humans
(Cui et al., 2000). By blocking phosphorylation of
VEGF receptor in laser induced mouse CNV model,
Kwak et al. demonstrated that VEGF was a major
stimulator of CNV development (Kwak, Okamoto,
Wood, & Campochiaro, 2000). Intravitreal anti-VEGF
monoclonal antibody prevented CNV formation in-
duced by laser treatment in monkey (Krzystolik et al.,
2002). Thus, VEGF appears to play a critical role in the
development of CNV in human exudative AMD and in
animal models induced by laser treatment.
It is evident that intravitreal triamcinolone can
suppress or inhibit CNV, and that VEGF is a major
stimulator of CNV, we ask the question whether tri-
amcinolone elicits its inhibitory action of CNV devel-
opment through inhibiting VEGF expression. As the
ﬁrst step to answer this question, we examined VEGF
expression in a normal adult rat model following in-
travitreal triamcinolone treatment.2. Materials and methods
2.1. Animals
Sprague–Dawley albino rats 6–7 weeks old (approx-
imately 250 g) were obtained from Charles River Lab-
oratories (Wilmington, MA). Animals were fed ablibitum with Purina lab chow and water with room
lighting consisting of a 12 h light: 12 h dark cycle.
2.2. Triamcinolone intravitreal injection
Animals were anesthetized with intraperitoneal in-
jections of Phenobarbital (Nembutal) (75 mg/kg). Pro-
paracaine hydrochloride of 0.5% (Alcon Labs, Inc.,
Forth Worth, TX) was used for additional topical an-
esthesia. Oﬂoxacin ophthalmic solution of 0.3% (Aller-
gan Inc, Irvene, CA) was applied to the ocular surface
before injection, and bacitracin ophthalmic ointment of
500 units/g (E. Fougera & Co., Melville, NY) after in-
jection, to prevent infection. Triamcinolone acetonide
(40 mg/ml) was obtained from Greenpark Compound-
ing Pharmacy (Houston, TX). A single dose of 320 lg in
a volume of 8 ll was injected into the vitreous under a
dissecting microscope using a Hamilton micro-injector
(Hamilton Co. Reno, Nevada). A 30 gauge needle was
ﬁrst used to make a punch incision 0.5 mm posterior to
the temporal limbus, and the Hamilton needle was then
inserted through the incision, approximately 1.5 mm
deep, angled towards the optic nerve until the tip of
needle was seen in the center of vitreous. Intravitreal
drug delivery was conﬁrmed by observing white triam-
cinolone suspension in the posterior vitreous under the
microscope. Eyes with lens injury from injection were
excluded from the study. Since rat vitreous volume is 56
ll (Berkowitz, Lukaszew, Mullins, & Penn, 1998), 320
lg of triamcinolone makes the ﬁnal intravitreal con-
centration of 5.7 mg/ml. The dosage used on rats in this
study is more than ﬁvefold higher than that of 1 mg/ml
used in human patients clinically (4 mg triamcinolone in
4 ml human vitreous volume). This high dose was cho-
sen because the pharmacokinetics of the drug in the rat
vitreous was unknown and because insuﬃcient dosing
was to be avoided. Balanced salt solution (BSS) (Alcon
Labs, Inc., Forth Worth, TX) of 8 ll was used as a
control and injected into the fellow eye of each animal.
Animals were sacriﬁced at three days (N ¼ 3), one week
(N ¼ 5), and two weeks (N ¼ 5) following injection and
processed for in situ hybridization. For Northern blot
analysis, 16 rats were treated with intravitreal triam-
cinolone and the fellow eye of each animal with BSS.
Animals were sacriﬁced three weeks after injection, and
the retinas were dissected for RNA isolation (see below).
2.3. Tissue preparation
Animals were euthanized with an overdose of phe-
nobarbital. The eyes were enucleated, an incision was
made in the cornea, and eyes were ﬁxed immediately in
4% formaldehyde in 0.1 M phosphate buﬀer (pH 7.4).
After 15 min in the ﬁxative, lenses were removed and
eyes were cut along the cornea–optic nerve axis into
halves. Tissues were further ﬁxed overnight in 4%
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phosphate buﬀer (pH 7.4). Tissues were embedded in
paraﬃn and sectioned at a thickness of 6 lm. The tri-
amcinolone and BSS injected eye tissue sections from
each animal were mounted on the same slide and pro-
cessed identically so that sections could be directly
compared with as little processing variability as possible.
2.4. In situ hybridization
Standard protocols of riboprobe in situ hybridization
were followed as described in detail previously (Gao,
Qiao, Hefti, Hollyﬁeld, & Knusel, 1997; Qiao, Hefti,
Knusel, & Noebels, 1996). Rat VEGF cDNA clone was
obtained as a generous gift from Dr. Salman Hyder at
the University of Texas in Houston. It consists of 570
bases of coding region and was inserted into plasmid
pBluecript SK (Hyder et al., 2000). For generation of
antisense VEGF riboprobes, the plasmid was linearized
with restriction enzyme BamH1. 35S-labeled antisense
riboprobes were transcribed using T7 polymerase and
Riboprobe Gemini System according to manufacturer’s
instructions (Promega Inc., Madison, WI). The tissue
sections were deparaﬃnized in xylene followed by re-
hydration. The sections were ﬁrst pretreated with 10 lg/
ml proteinase K at 37 C for 20 min, 0.25% acetic an-
hydrite and 0.1 M triethanolamide for 10 min. The tis-
sue sections were then incubated at 50 C on a slide
warmer for 18± 2 h with the probe solutions containing
5 · 106 cpm/ml 35S-labeled probes, 50% formamide, 10%
dextran sulfate, 300 mM NaCl, 0.5 mg/ml tRNA, 10 lM
DTT, 0.02% Ficoll, 0.02% polyvinyl-pyrolidone, 0.02%
BSA, and 1 mM EDTA in 10 mM Tris-HCl (pH 8.0).
Following hybridization, the slides were rinsed in
4 · SSC (SSC: 150 mM NaCl and 15 mM sodium cit-
rate), digested with 20 lg/ml RNase A at 37 C for 30
min, washed through descending concentrations of SSC
to 0.1 ·SSC at 60–70 C. The slides were then dehy-
drated in ethanol, dried and coated with NTB-2 liquid
emulsion (Kodak Inc., Rochester, NY). Following ex-
posure in the dark for four weeks, the emulsion was
developed and sections were counter-stained with he-
matoxylin.
2.5. Image quantiﬁcation
To quantitate and compare VEGF mRNA signals in
retinal cells, image analysis was performed using com-
puter enhanced video densitometry (Southern Micro
Instruments, Atlanta, GA). VEGF mRNA positive cells
were deﬁned as those cells over which silver grains ex-
ceed ﬁve times the background value. Silver grain den-
sities in the RPE, INL and ganglion cell layers were
determined separately and compared between the tri-
amcinolone and BSS control groups. For each group,
three eyes were included with three tissue sections ex-amined for each eye, and three window areas were an-
alyzed in each section. A student t-test was used for
statistical analysis between the two groups.
2.6. Northern blot
Three weeks after intravitreal injection of triamcino-
lone and of BSS in the fellow eye of each animal, 16 rats
were sacriﬁced. There were still small amounts of white
triamcinolone precipitates in the vitreous when eyes
were enucleated. The retinas were dissected out and
pooled, and total retinal RNA was isolated as described
previously (Gao & Hollyﬁeld, 1995). The antisense
VEGF riboprobe was synthesized as described above
labeling with 32P-CTP. Northern blot was performed
using standard methods: the total RNA of 30 lg was
separated on 1% agarose formaldehyde-denaturing gel.
For one week group, 10 lg RNA was used. The RNA
was blotted to 0.2 lm neutral nylon membranes
(Schleicher & Schuell, Keene, NH) and hybridized to
32P-labeled VEGF probe (3 · 106 cpm/ml). The mem-
brane was then washed in graded SSC, dried, and ex-
posed to PhosphorImager plate (Molecular Dynamics,
Eugene, OR). Relative abundance of mRNA was
quantiﬁed by reading the plate. VEGF mRNA signals at
4.2 kb were used to perform the densitometry. b-actin
mRNA was also examined and used as an internal
control. The same blot was re-probed and hybridized to
32P-labeled b-actin probe. The ratio of VEGF/b-actin
densities was then used for comparison between the
triamcinolone and BSS control groups. Northern anal-
ysis was repeated three times, and t-test was used for
statistical analysis.3. Results
3.1. VEGF mRNA expression pattern in rat retina
Using radio-labeled rat VEGF riboprobes, in situ
hybridization was performed on animal eyes three days,
one week, and two weeks following intravitreal triam-
cinolone injection. As shown in Fig. 1, VEGF mRNA
expression signals are localized in the retinal pigment
epithelium (RPE), cells in the inner nuclear layer (INL),
and some ganglion cells. VEGF mRNA signal intensity
is the highest in the RPE. Nearly every RPE cell is po-
sitive for VEGF mRNA signals, with clustered signals in
each RPE cell around the nuclei. In the INL, VEGF
signals appear patchy over cells, less clustered than in
the RPE, and the signals are not as intense as in the
RPE. VEGF signals in the ganglion cells are at moder-
ate level, and only a sub-population of ganglion cells is
positive for VEGF. Following intravitreal triamcinolone
injection (Fig. 1B–D), VEGF mRNA expression signals
are very comparable with those in control eye injected
Fig. 1. In situ hybridization showing VEGF mRNA expression in rat retina with intravitreal balanced salt saline (A) or intravitreal triamcinolone
treatments for three days (B), one week (C), and two weeks (D). A, B, C, D, ﬁne dark particles of VEGF mRNA signals are localized in the RPE, cells
in the inner nuclear layer, and some ganglion cells. No signiﬁcant diﬀerence of VEGF expression is noticed between the balanced salt saline and
triamcinolone groups. E, Clustered VEGF signals are present in nearly every RPE cell. F, Patchy signals are found in the inner nuclear layer and in
some ganglion cells. RPE: retinal pigment epithelium. ONL: outer nuclear layer. INL: inner nuclear layer. GCL: ganglion cell layer. Scale bar¼ 100
lm (A,B,C,D); 50 lm (E,F).
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ganglion cells. Image analysis using densitometry to
compare signal intensity in each layer between the tri-
amcinolone and saline group retinas was performed and
showed no statistically signiﬁcant diﬀerence (p > 0:05)
in signal intensity between them (Fig. 2). There was also
no diﬀerence of signal intensity among three days, one
week and two week triamcinolone groups in any cell
layers. Thus, triamcinolone does not change VEGF
mRNA expression from three days to two weeks after
intravitreal injection. To obtain a baseline VEGF
mRNA expression in retina, normal adult rat retina
without any intervention was examined, and VEGF
signals are the same as in retinas with BSS injection (Fig.
1A). Thus, intravitreal injection itself does not alter
VEGF expression in retina.3.2. No quantitative change of VEGF mRNA level by
triamcinolone
Northern blot analysis was performed to conﬁrm that
the signals in the in situ hybridization study were VEGF
mRNA by checking its molecular weight. Since in situ
hybridization is only a semi-quantitative method for
signal quantiﬁcation, but an excellent technique to de-
tect the localization of mRNA signals, northern blot was
also utilized to further quantitate and compare VEGF
mRNA expression levels between the triamcinolone and
BSS control groups using rat VEGF riboprobes (see
Section 2). Total RNA was isolated from retinas of eyes
treated for three weeks with either intravitreal triam-
cinolone or BSS. Northern blot revealed a single char-




























Fig. 2. Image analysis of VEGF in situ hybridization signals demon-
strating optical densities in the retinal pigment epithelium (RPE), inner
nuclear layer (INL) and ganglion cell layer (GCL). Statistical analysis
with t-test shows no signiﬁcant diﬀerence of VEGF signals between
balanced salt saline (BSS) and triamcinolone (TAC) groups after three
days, one week, or two weeks intravitreal treatments.
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conﬁrms that the signals detected in in situ hybridization
and in Northern blot are indeed VEGF mRNA. b-actin
mRNA expression was also examined and used as an
internal control since b-actin is known to be a house-
keeping gene and expressed at a constant level (Oue,
Taira, Shima, Miyazaki, & Puri, 1999). Relative levels of
VEGF mRNA were expressed as a ratio of the band
density divided by that of b-actin. Densitometry analysis
shows no signiﬁcant diﬀerence of VEGF mRNA ex-
pression in triamcinolone over that in BSS control
groups (p > 0:05) (Fig. 3). Thus, Northern blot analysisFig. 3. Northern blot analysis of VEGF mRNA expression in rat
retina treated for three weeks with a single dosage of intravitreal tri-
amcinolone (TAC) or balanced salt saline (BSS) as control. b-actin
mRNA expression is also examined and used as an internal control.
(A) VEGF mRNA signals show as a single band with molecular weight
of 4.2 kb. b-actin mRNA signals from the same retinas are serve as
internal control. (B) Densitometry analysis shows no diﬀerence be-
tween triamcinolone and BSS control groups in the ratio of BDNF/b-
actin densities.conﬁrms the in situ hybridization results and shows that
VEGF mRNA expression level is not changed 3 weeks
following intravitreal triamcinolone treatment.4. Discussion
In the present study, VEGF mRNA expression was
examined in normal adult rat retina. Our in situ results
are very comparable with other reports (Yi et al., 1997)
demonstrating that VEGF expression is present in the
RPE, cells in the INL and ganglion cells (Fig. 1). VEGF
mRNA shows a molecular weight at 4.2 kb in northern
blot consistent with prior studies (Gao et al., 2001). The
VEGF positive cells in the INL were proved to be
Muller cells in mouse (Pierce et al., 1995). Only a small
portion of ganglion cells expresses VEGF, however, it
remains to be determined which speciﬁc sub-population
of ganglion cells.
The exact eﬀect of steroid on VEGF expression in the
retina is still unknown. There is conﬂicting data in the
literature regarding the eﬀect of glucorticoids on VEGF
expression. It has been reported that triamcinolone re-
duces VEGF expression in cultured aortic vascular
smooth muscle cells (Nauck, Karakiulakis, Perruchoud,
Papakonstantinou, & Roth, 1998). Glucocorticosteroid
also reduces VEGF mRNA and protein expression in
cultured eosinophils (Horiuchi & Weller, 1997). On the
other hand, strong evidence exists that steroid has no
eﬀect on VEGF expression. By comparing VEGF ex-
pression in human hemangioma specimen with and
without steroid treatment, Hasan et al. found that tri-
amcinolone injection does not change tissue VEGF ex-
pression (Hasan, Tan, Gush, Peters, & Davis, 2000). In
the present study, intravitreal triamcinolone does not
show any signiﬁcant change of VEGF mRNA expres-
sion in rat retina three weeks after treatment (Figs. 2 and
3). As these results seem to segregate between in vivo
and in vitro experiments, the diﬀerence could be due to
altered environmental conditions. Since basic ﬁbroblast
growth factor (bFGF) has also been implicated in the
development of neovascularization, bFGF expression
has been evaluated with steroid treatment. In cultured
choroidal endothelial cells, triamcinolone signiﬁcantly
reduces bFGF expression (Wang, Friedrichs, Eichler,
Hoﬀmann, & Wiedemann, 2002); whereas in excised
human hemangioma specimen, triamcinolone does not
change bFGF expression (Hasan et al., 2000). It is
possible that triamcinolone’s eﬀects on cells are deter-
mined by environment these cells are located. Experi-
mental results from in vitro studies can not directly be
compared with those from in vivo studies.
The mechanisms by which triamcinolone suppresses
or inhibits the development of CNV remain unknown. It
remains to be determined whether triamcinolone regu-
lates VEGF expression in CNV membrane in exudative
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laser treatments, and whether triamcinolone regulates
VEGF expression in the retina and RPE which are ad-
jacent to CNV membrane.
It is possible that triamcinolone may inhibit VEGF
expression in abnormal or diseased RPE. A recent study
showed that when only the RPE over-expressed VEGF,
which was induced by a sub-retinal recombinant ade-
novirus vector expressing VEGF, CNV formed in the
adjacent region close to the RPE (Spilsbury, Garrett,
Shen, Constable, & Rakoczy, 2000). Furthermore, the
severity and extent of the resulting CNV were aﬀected
by controlling the amount of VEGF expression. Others
reported that migrating RPE, which are not normally
present in the retina, in the CNV membrane expressed
VEGF (Spilsbury et al., 2000). However, in animal
model with systemic VEGF over-expression achieved
through transgenic mouse techniques, pre-retinal and
intra-retinal neovascularization developed, but CNV did
not occur (Okamoto et al., 1997). Thus CNV may be
stimulated by focal over-expression of VEGF, at least
partly from the diseased RPE. Since triamcinolone in-
hibits CNV formation (Challa et al., 1998; Ciulla et al.,
2001; Danis et al., 1996; Jonas et al., 2003; Penfold et al.,
1995; Ranson et al., 2002), it remains to be determined
whether triamcinolone reduces VEGF expression in
focal diseased RPE in the area where CNV happens
adjacently, whether triamcinolone inhibits RPE migra-
tion to the CNV membrane.
It is known that macrophages are present in human
CNV membranes, and macrophage accumulation in the
sub-retinal space peaks before the development of CNV
(Grossniklaus et al., 2002). Studies show that macro-
phages can produce VEGF (Ishibashi et al., 1997; Itaya
et al., 2001). Several studies implicate macrophages as
the major source of VEGF in the CNV membrane
(Grossniklaus et al., 2002; Yi et al., 1997). Studies of
human endometriosis development show similar ﬁnd-
ings: macrophages are the major source of VEGF in
human endometriosis tissues (McLaren et al., 1996).
Since steroid can inhibit macrophage migration (Bucala,
1998), it is possible that triamcinolone reduces CNV
formation through inhibiting macrophage migration to
the sub-retinal CNV membrane. Further experiments
need to be done to examine whether triamcinolone also
suppresses VEGF expression in macrophages.
Development of CNV in human exudative AMD is a
complicated process and multiple growth factors may be
involved (Frank, Amin, Eliott, Puklin, & Abrams,
1996). Another angiogenesis factor, bFGF, may also
play a role in the development of CNV (Campochiaro,
Soloway, Ryan, & Miller, 1999). It has been reported
that triamcinolone inhibited bFGF-induced prolifera-
tion of choroidal vascular endothelium in vitro which
leads to vessel formation (Wang et al., 2002). Studies
also show that triamcinolone signiﬁcantly down-regu-lates intercellular adhesion molecule-1 (ICAM-1) ex-
pression and decreases paracellular permeability in
cultured epithelium, and thus potentially strengthens the
barrier function of the RPE and reduces sub-retinal
edema (Penfold et al., 2000). Triamcinolone also down-
regulates MHC-II expression and thus reduces in-
ﬂammatory markers and endothelial cell permeability
(Penfold, Wong, Gyory, & Billson, 2001). Thus triam-
cinolone may aﬀect multiple factors to inhibit the de-
velopment of CNV in human AMD.References
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